{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-021064","form_type":"8-K","ticker":"CRDF","cik":"0001213037","company_name":"Cardiff Oncology, Inc.","filed_at":"2022-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.157727+00:00","generated_at":"2026-06-24T03:45:39.072762+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cardiff Oncology Q2 2022: $122M cash; preclinical ovarian data shows onvansertib + olaparib survival benefit","bullets":["Cash, equivalents, and short-term investments of ~$122M as of June 30, 2022; net cash used in Q2 2022 was $6.7M, up from $4.3M in Q2 2021.","R&D expenses rose to $7.45M from $4.12M YoY, driven by CMC and clinical pharmacology studies for onvansertib.","Preclinical ovarian cancer data at AACR: onvansertib + olaparib showed statistically significant survival benefit vs either agent alone in three PDX models.","Phase 2 mCRPC trial: 75% (15/20) of most dose-dense arm achieved stable disease or partial response at 12 weeks; response correlated with PTEN/MTOR mutations."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-021064","json":"https://secwatch.observer/filing/0001628280-22-021064.json","markdown":"https://secwatch.observer/filing/0001628280-22-021064.md","text":"https://secwatch.observer/filing/0001628280-22-021064.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213037/000162828022021064/0001628280-22-021064-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213037/000162828022021064/crdf-20220804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T03:45:39.072762+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}